News
2025.10.09
Launch of the World’s First Vaccine to Prevent Serotype III α-Hemolytic Lactococcosis in Yellowtail
Kyoritsu Seiyaku Corporation (head office: Chiyoda-ku, Tokyo; CEO: Takaaki Takai) launches the trivalent oil-adjuvant vaccine to prevent Type III α-hemolytic lactococcosis in yellowtail from May 12, 2025.
The world’s first! Launch of Trivalent oil-adjuvant Vaccine to Prevent α-Hemolytic Lactococcosis, the Most Damaging Disease in Yellowtail Farming
The only vaccine that covers all identified serotypes of α-hemolytic lactococcosis
In Japanese marine aquaculture, α-Hemolytic Lactococcosis (*1) is one of the most damaging diseases, particularly affecting yellowtails (such as yellowtail and greater amberjack) and striped jack. Previously, only Types I and Ⅱ serotypes of α-hemolytic lactococcosis were known. In 2021, a new Type Ⅲ serotype was identified in multiple marine fish species and resulted in significant economic losses. (*2) Unfortunately, the currently approved vaccines could not prevent Type Ⅲ, which prompted the development of this new vaccine.
This vaccine is administered via intraperitoneal injection in yellowtails. It can cover all currently identified serotypes of α-hemolytic lactococcosis for yellowtails.
We remain committed to developing new fish vaccines to ensure the safe and sustainable production of farmed fish.
www.kyoritsuseiyaku.co.jp/en/products/detail/product_20227.html
(*1) First identified in 1974, this fish disease has inflicted substantial economic losses on the aquaculture industry because infected yellowtails are deemed unmarketable.
(*2) Survey Results on a Newly Identified Type of α-Hemolytic Lactococcosis.
【Product Overview】
The World’s First Vaccine to Prevent Serotype III α-Hemolytic Lactococcosis in Yellowtail. The use of this vaccine provides efficacy against all currently identified serotypes.
Since this vaccine is an oil adjuvanted vaccine that can also be used for amberjack, it is expected to provide long-lasting immunity compared to water-based vaccines.
This vaccine is administered via intraperitoneal injection in yellowtails. It can cover all currently identified serotypes of α-hemolytic lactococcosis for yellowtails.
We remain committed to developing new fish vaccines to ensure the safe and sustainable production of farmed fish.
www.kyoritsuseiyaku.co.jp/en/products/detail/product_20227.html
(*1) First identified in 1974, this fish disease has inflicted substantial economic losses on the aquaculture industry because infected yellowtails are deemed unmarketable.
(*2) Survey Results on a Newly Identified Type of α-Hemolytic Lactococcosis.
【Product Overview】
The World’s First Vaccine to Prevent Serotype III α-Hemolytic Lactococcosis in Yellowtail. The use of this vaccine provides efficacy against all currently identified serotypes.
Since this vaccine is an oil adjuvanted vaccine that can also be used for amberjack, it is expected to provide long-lasting immunity compared to water-based vaccines.